117 related articles for article (PubMed ID: 2856451)
1. [The estrogen receptor in breast carcinoma in male patients and the tamoxifen response].
Gómez Cruz P; Rivadeneyra Hinojosa J; García-Alonso H; Rábago Velasco M
Ginecol Obstet Mex; 1988 Nov; 56():310-4. PubMed ID: 2856451
[No Abstract] [Full Text] [Related]
2. [Tamoxifen-induced progesterone receptors in breast tumors].
Tsyrlina EV; Semiglazov VF; Nurgaziev KSh; Ivanova OA
Vopr Onkol; 1991; 37(9-10):916-21. PubMed ID: 1842650
[TBL] [Abstract][Full Text] [Related]
3. Impact of estrogen receptor expression and other clinicopathologic features on tamoxifen use in ductal carcinoma in situ.
Hird RB; Chang A; Cimmino V; Diehl K; Sabel M; Kleer C; Helvie M; Schott A; Young J; Hayes D; Newman L
Cancer; 2006 May; 106(10):2113-8. PubMed ID: 16596655
[TBL] [Abstract][Full Text] [Related]
4. Phase II clinical trial of N-(4-Hydroxyphenyl)retinamide and tamoxifen administration before definitive surgery for breast neoplasia.
Singletary SE; Atkinson EN; Hoque A; Sneige N; Sahin AA; Fritsche HA; Lotan R; Lu T; Hittelman WN; Bevers TB; Stelling CB; Lippman SM
Clin Cancer Res; 2002 Sep; 8(9):2835-42. PubMed ID: 12231524
[TBL] [Abstract][Full Text] [Related]
5. Tamoxifen approved for node-negative breast cancer patients.
Oncology (Williston Park); 1990 Aug; 4(8):15-6. PubMed ID: 2145007
[No Abstract] [Full Text] [Related]
6. Predicting response to tamoxifen in metastatic breast cancer.
Connor JL; Foley JF; Lemon HM
Nebr Med J; 1986 Dec; 71(12):422-6. PubMed ID: 3796760
[No Abstract] [Full Text] [Related]
7. [Radiotherapy and tamoxifen facilitate breast-preserving treatment of ductal carcinoma in situ of the breast].
Sautter-Bihl ML
Strahlenther Onkol; 1999 Dec; 175(12):620-1. PubMed ID: 10633790
[No Abstract] [Full Text] [Related]
8. The nature of tamoxifen action in the control of female breast cancer.
Kodama M; Kodama T
In Vivo; 2001; 15(4):319-25. PubMed ID: 11695224
[TBL] [Abstract][Full Text] [Related]
9. HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study.
Elledge RM; Green S; Ciocca D; Pugh R; Allred DC; Clark GM; Hill J; Ravdin P; O'Sullivan J; Martino S; Osborne CK
Clin Cancer Res; 1998 Jan; 4(1):7-12. PubMed ID: 9516946
[TBL] [Abstract][Full Text] [Related]
10. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA
Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543
[TBL] [Abstract][Full Text] [Related]
11. Assessment of response to tamoxifen among Iraqi patients with advanced breast cancer.
al-Alwan NA; al-Kubaisy W; al-Rawaq K
East Mediterr Health J; 2000; 6(2-3):475-82. PubMed ID: 11556039
[TBL] [Abstract][Full Text] [Related]
12. Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer.
Newby JC; Johnston SR; Smith IE; Dowsett M
Clin Cancer Res; 1997 Sep; 3(9):1643-51. PubMed ID: 9815855
[TBL] [Abstract][Full Text] [Related]
13. Tamoxifen in the treatment of advanced breast cancer. Clinical experience at Siriraj Hospital.
Tepmongkol P; Suphaphongs N; Chantarakul N; Thansakul A
J Med Assoc Thai; 1986 Feb; 69(2):96-102. PubMed ID: 3011939
[No Abstract] [Full Text] [Related]
14. Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer.
Foekens JA; Diamandis EP; Yu H; Look MP; Meijer-van Gelder ME; van Putten WL; Klijn JG
Br J Cancer; 1999 Feb; 79(5-6):888-94. PubMed ID: 10070886
[TBL] [Abstract][Full Text] [Related]
15. The management of locally advanced carcinoma of the breast by Nolvadex (tamoxifen): a pilot study.
Campbell FC; Morgan DA; Bishop HM; Benton FM; Blamey RW; Elston CW; Nicholson RI; Griffiths K
Clin Oncol; 1984 Jun; 10(2):111-5. PubMed ID: 6734002
[TBL] [Abstract][Full Text] [Related]
16. [The importance of steroid receptors for the prognosis and hormone treatment of breast cancer patients: a retrospective study in Southeastern Netherlands].
Voogd AC; Crommelin MA; Repelaer van Driel OJ; Tutein Nolthenius-Puylaert MC; Vreugdenhil G; Coebergh JW
Ned Tijdschr Geneeskd; 1998 Aug; 142(31):1772-8. PubMed ID: 9856143
[TBL] [Abstract][Full Text] [Related]
17. Ductal carcinoma-in-situ.
Wickerham DL
J Clin Oncol; 2001 Sep; 19(18 Suppl):98S-100S. PubMed ID: 11560982
[No Abstract] [Full Text] [Related]
18. Tamoxifen induces heparanase expression in estrogen receptor-positive breast cancer.
Cohen I; Maly B; Simon I; Meirovitz A; Pikarsky E; Zcharia E; Peretz T; Vlodavsky I; Elkin M
Clin Cancer Res; 2007 Jul; 13(14):4069-77. PubMed ID: 17634531
[TBL] [Abstract][Full Text] [Related]
19. Estrogen and progesterone receptors in neoplastic cells of metastatic pleural effusion of breast carcinoma before and after tamoxifen therapy. Correlation with the clinical response.
Di Lorenzo D; Zaniboni A; Simoncini E; Marpicati P; Montini E; Alghisi A; Gorni F; Marini G
Chemioterapia; 1986 Aug; 5(4):232-6. PubMed ID: 3769044
[TBL] [Abstract][Full Text] [Related]
20. High nuclear grade and negative estrogen receptor are significant risk factors for recurrence in DCIS.
Roka S; Rudas M; Taucher S; Dubsky P; Bachleitner-Hofmann T; Kandioler D; Gnant M; Jakesz R
Eur J Surg Oncol; 2004 Apr; 30(3):243-7. PubMed ID: 15028303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
